Article
The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
AIDS (London, England) - 31 Jul 2013
Rivero-Juarez Antonio, Lopez-Cortes Luis F, Camacho Angela, Caruz Antonio, Torres-Cornejo Almudena, Martinez-Dueñas Loreto, Ruiz-Valderas Rosa, Torre-Cisneros Julian, Gutierrez-Valencia Alicia, Rivero Antonio
Abstract excerpt
OBJECTIVE: To evaluate the IL28B effect on hepatitis C virus (HCV) decline during first weeks of treatment according to HCV-1 subtypes. METHODS: Patients coinfected with HIV/HCV genotype 1 and naive to peginterferon-alpha-2a and ribavirin (Peg-IFN-alpha-2a/RBV) were included. Plasma HCV-RNA was measured at baseline, and then at weeks 1, 2, and 4. HCV-1 subtype (1a or 1b) was determined. HCV viral decline was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.